Business Description
Clinuvel Pharmaceuticals, founded in 1999 and based in Melbourne, Australia, develops medicines for people living with rare genetic, skin, and metabolic conditions across multiple countries. Its most advanced product, SCENESSE, is approved to protect adults with erythropoietic protoporphyria from the severe pain caused by light exposure. The company is also working on a range of treatments targeting neurological and hormonal disorders, as well as conditions such as vitiligo, and sells skincare products designed to support DNA repair and skin pigmentation in people sensitive to light.
